Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User "Jordan_cadagan" shares 11-month progress using minoxidil and finasteride for hair growth, with impressive results. Users discuss application methods, ice baths possibly helping, and daily dosages.

Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

HairClone received grant money to start work after crowdfunding failed. They aim to offer treatments in early 2021, pending UK FDA licensing.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

The conversation discusses hair loss treatment progress 11 weeks after a crown transplant. The user is using minoxidil every two days and biotin daily, without finasteride.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.

The post discusses an 11-month hair loss treatment journey using dutasteride, minoxidil, nizoral, and 1.5mm derma rolling. The responses inquire about the frequency of derma rolling and express optimism for further progress.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.